EP 4 receptor agonist, compositions and methods thereof

Details EP 4 receptor agonist, compositions and methods thereof EP 4 receptor agonist, compositions and methods thereof

2007-07-03

2007-07-03

Habte, Kahsay (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S022000, C546S192000, C546S248000, C514S327000

Reexamination Certificate

active

11146992

ABSTRACT:
This invention relates to potent selective agonists of the EP4subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 6043275 (2000-03-01), Maruyama et al.
patent: 6344477 (2002-02-01), Sharif
patent: 6747037 (2004-06-01), Old et al.
patent: 2002/0065308 (2002-05-01), Cameron et al.
patent: 0 008 186 (1979-07-01), None
patent: 0855389 (1998-01-01), None
patent: 1114816 (2001-07-01), None
patent: 1 524 818 (1974-11-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 00/21542 (2000-04-01), None
patent: WO 01/46140 (2001-06-01), None
patent: WO 01/70702 (2001-09-01), None
patent: WO 02/24647 (2002-03-01), None
patent: WO 02/42268 (2002-05-01), None
patent: WO 02/060863 (2002-08-01), None
patent: WO 01/72268 (2002-10-01), None
patent: WO 02/077168 (2002-10-01), None
patent: WO 03/047417 (2003-06-01), None
patent: WO 03/047513 (2003-06-01), None
patent: WO 03/105724 (2003-12-01), None
patent: WO 03/105847 (2003-12-01), None
patent: WO 03/105868 (2003-12-01), None
patent: WO 2004/063158 (2004-07-01), None
P. Barraclough et al., “Heterocyclic Prostaglanding Analoughes. Part 4, Piperazine-2,5-diones, Pyrazolidine-3,5-diones, 1,2,4-Triazolidinediones, 1,3,4-Oxadiiazolidine-diones and 1,3,4-Thiadiazolidinediones”, 1980, pp. 2096-2105, J.C.S. Perkin I.
R. A. Schumer et al., “The Nerve of Glaucoma”, 1994, pp. 37-44, vol. 112, Arch Ophthalmol.
M. Weinreb et al., “Different Pattern of Alkaline Phosphatase, Osteopontin, and Osteocalcin Expression in Developing Rate Bone Visualized by in Situ Hybridization”, 1990, vol. 5, No. 8, J. of Bone and Mineral Research.
D. A. Dartt et al., “Localization of Nerves Adjacent to Goblet Cells in Rat Conjunctiva” 1994, pp. 933-1000, vol. 14, Curr. Eye Res.
L. Dandona et al., “Selective Effects of Experimental Glaucoma on Axonal Transport by Retinal Ganglion Cells to the Dorsal Lateral Geniculate Nucleus”, 1991, pp. 1593-1599, vol. 32, No. 5, Investigative Ophthalmology & Visual Sciences.
E. M. Ross, “Mechanisms of Drug Action and the Realtionship Between Drug Concentration and Effect”, pp. 29-41, chapter 2, Goodman and Gilman's Pharmacological Basis of Therapeutics, (1996).
I. K. Gipson et al., “Mucin Genes Expressed by the Ocular Surface Epithelium”, 1997, pp. 81-98, vol. 16, No. 1, Progress in Retinal and Eye Research.
D. M. Shinar et al., “Expression of alphaV and Beta3Integrin Subunits in Rat Osteoclasts in Situ”, 1993, pp. 403-414, vol. 8, No. 4, J. of Bone and Mineral Research.
M. A. Lemp et al., “Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes”, 1995, pp. 221-232, vol. 21, No. 4, CLAO Journal.
M. Abramovitz et al., “The Utilization of Recombinant Prostanoid Receptors to Determine the Affinities and Selectivities of Prostaglandins and Related Analogs”, 2000, pp. 285-293, vol. 1483, Biochimica et Biophysica Acta.
P. Chomczynski et al., “Single-Step Mehtod of RNA Isolation by Acid Guanidinium Thiocyanante-Phenol-Chloroform Extraction”, 1987, pp. 156-159, vol. 162, Analytical Biochemistry.
S.B. Rodan et al., “Growth Stimulation of Rat Calvaria Osteoblastic Cells by Acidic Fibroblast Growth Factor”, 1987, pp. 1917-1923, vol. 121, No. 6, Endocrinology.
M. Abramovitz et al., “Human Prostanoid Receptors: Cloning and Characterization”, 1995, pp. 499-504, vol. 23, Advances in Prostaglandin Thromboxane, and Leukotriene Research.
J. E. Larco et al., “Epithelioid and Fibroblastic Rat Kidney Cell Clones: Epidermal Growth Factor (EGF) Receptors and the Effect of Mouse Sarcoma Virus Transformation”, 1978, pp. 335-342, vol. 94, J. Cell Physiol.
T. J. Hodgkinson et al., “Practical Asymmetric Synthesis of Both Enantiomers of 6-(Hydroxymethyl) piperidin-2-one”, pp. 1141-1144, Synthesis, (1998).

Affiliated with

Also associated with

Rating

EP 4 receptor agonist, compositions and methods thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EP 4 receptor agonist, compositions and methods thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP 4 receptor agonist, compositions and methods thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3779309